Malin Life Sciences Holdings Ltd - Nov 16, 2021 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role: Common director with Issuer, 10%+ Owner
Signature: /s/ Pat Jennings, Chief Financial Officer
Stock symbol: PSTX
Transactions as of: Nov 16, 2021
Transactions value $: $2,731,889
Form type: 4
Date filed: 11/18/2021, 07:24 PM
Next filing: Nov 23, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	COMMON STOCK	Purchase	$198K	+27.7K	+0.3%	$7.17	9.22M	Nov 16, 2021	Direct	F1
transaction	PSTX	COMMON STOCK	Purchase	$2.02M	+280K	+3.04%	$7.21	9.5M	Nov 17, 2021	Direct	F1
transaction	PSTX	COMMON STOCK	Purchase	$512K	+71.3K	+0.75%	$7.18	9.57M	Nov 18, 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported prices in Column 4 are weighted average prices. Those shares were purchased in multiple transactions at per share prices ranging from $7.06 to $7.25 on 11/16/2021; $6.97 to $7.37 on 11/17/2021; and $6.84 to $7.29 on 11/18/2021. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

The reported prices in Column 4 are weighted average prices. Those shares were purchased in multiple transactions at per share prices ranging from $7.06 to $7.25 on 11/16/2021; $6.97 to $7.37 on 11/17/2021; and $6.84 to $7.29 on 11/18/2021. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.